Enzo Biochem (FRA:EZB) LT-Debt-to-Total-Asset : 0.03 (As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Enzo Biochem's long-term debt to total assests ratio for the quarter that ended in Jan. 2024 was 0.03.

Enzo Biochem's long-term debt to total assets ratio declined from Jan. 2023 (0.15) to Jan. 2024 (0.03). It may suggest that Enzo Biochem is progressively becoming less dependent on debt to grow their business.

Enzo Biochem LT-Debt-to-Total-Asset Historical Data

The historical data trend for Enzo Biochem's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem LT-Debt-to-Total-Asset Chart

Enzo Biochem Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.19

0.17

0.11

0.03

Enzo Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.15	0.15	0.03	0.03	0.03

Enzo Biochem LT-Debt-to-Total-Asset Calculation

Enzo Biochem's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2023 is calculated as

LT Debt to Total Assets (A: Jul. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jul. 2023 )	/	Total Assets (A: Jul. 2023 )
	=	3.1	/	110.18
	=	0.03

Enzo Biochem's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

LT Debt to Total Assets (Q: Jan. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2024 )	/	Total Assets (Q: Jan. 2024 )
	=	2.771	/	90.953
	=	0.03

Enzo Biochem (FRA:EZB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Enzo Biochem LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (FRA:EZB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (FRA:EZB) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

NOTV VNRX BIOQ STIM PSNL PRE OCX MDXH TTOO XGN TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

ENZ:USA

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Enzo Biochem (FRA:EZB) Headlines

No Headlines